Estudio de factibilidad para la creación de una empresa dedicada a la fabricación y comercialización de bolsos y accesorios para mujer en la ciudad de Pereira

CD-T 657.8 C178; 138 pnace la idea de crear una empresa de fabricación y comercialización de bolsos el 20 de junio de 2009 empresa creada y conformada, como Infinity, que desea incursionar en el mercado de los accesorios, en nuestro caso son los bolsos elaborados de forma artesanal con diferentes materiales tales como cuerinas con procesos de estampación y diseños innovadores que se puedan adaptar a las necesidades de las mujeres.Universidad Libre Seccional Pereir

La imagen y la narrativa como herramientas para el abordaje psicosocial en escenarios de violencia. Departamento de Antioquia

En el desarrollo de este trabajo se abordan los diferentes contextos en escenarios de violencia utilizando como herramienta principal para el análisis psicosocial la imagen y la narrativa. Con base en ello, primero se realizó la construcción del estudio conjunto del relato de Luz, analizado la narración de esta y los elementos que direccionaron movilizar de un hecho traumático de violencia hasta unas acciones resilientes. Siguiente a este primer ejercicio y habiendo identificado los emergentes psicosociales, se realizó de forma reflexiva un análisis orientado a consolidar y destacar conceptos en el contexto que luego sirvieron de apoyo para la construcción de una serie de preguntas de tipo entrevista que permitiera un acercamiento exploratorio de apoyo para el abordaje. Habiendo hecho uso del análisis reflexivo del relato, se realizó la aplicación enfocada en el Caso de Masacre en el Salado, cuyos relatos en su contenido facilitaban un abordaje psicosocial, gracias a la aplicación conceptual previa de la búsqueda de elementos aplicados al contexto en escenarios de violencia del relato, permitió un análisis reflexivo conjunto para proponer estrategias estructuradas y orientadas para que de forma analítica se pudiera incorporar la resiliencia y el empoderamiento como factor diferenciador. Finalmente, se comparte un link con el video de la foto voz, que da cuenta de la experiencia tras la exploración de escenarios de violencia en cinco municipios del departamento de Antioquia.The development of this work addresses different contexts in scenarios of violence using imagery and narrative as the main tools for psychosocial analysis. Based on this, the construction of a joint study of Luz's story was first carried out, analyzing her narration and the elements that directed the transformation from a traumatic experience of violence to resilient actions. Following this initial exercise and having identified the psychosocial emergent themes, a reflexive analysis was conducted to consolidate and highlight concepts in the context, which then served as a support for the construction of a series of interview questions aimed at exploratory engagement. After utilizing the reflexive analysis of the narrative, the application was focused on the case of the Salado Massacre, whose narratives provided content for a psychosocial approach. The prior conceptual application of elements related to the context of violence in the narrative allowed for a joint reflexive analysis to propose structured and oriented strategies that could incorporate resilience and empowerment as differentiating factors. Finally, a link is shared to a video of photo voice images that shed light on the experiences from the exploration of violence scenarios in five municipalities in the department of Antioquia

Memorias de investigación: Feria de Semilleros y Jornadas de Investigación de uniminuto, Seccional Antioquia - Chocó.

Feria de Semilleros y Jornadas de Investigación de uniminuto, Seccional Antioquia - Chocó.Esta publicación busca divulgar investigaciones y producción académica en diferentes disciplinas, realizadas por estudiantes y docentes de UNIMINUTO Seccional Antioquia – Chocó, así como dar a conocer los semilleros de investigación que participaron en la V Feria de Semilleros, con el fin de visibilizar el trabajo que realiza el Centro de Investigación para el Desarrollo de UNIMINUTO Bello —CIDUB—, con respecto a debates académicos y espacios de interlocución. Igualmente, permite que la comunidad educativa conozca los temas de investigación y las discusiones que se están dando entre los semilleros y grupos de investigación, para así buscar puntos de encuentro y sinergias entre los investigadores. Adicionalmente, el texto se convierte en una invitación para que se vinculen otros investigadores, docentes, estudiantes e incluso otras instituciones a los procesos investigativos coordinados desde el CIDUB

Memorias de investigación: Feria de Semilleros y Jornadas de Investigación de uniminuto, Seccional Antioquia - Chocó.

Feria de Semilleros y Jornadas de Investigación de uniminuto, Seccional Antioquia - Chocó.Esta publicación busca divulgar investigaciones y producción académica en diferentes disciplinas, realizadas por estudiantes y docentes de UNIMINUTO Seccional Antioquia – Chocó, así como dar a conocer los semilleros de investigación que participaron en la V Feria de Semilleros, con el fin de visibilizar el trabajo que realiza el Centro de Investigación para el Desarrollo de UNIMINUTO Bello —CIDUB—, con respecto a debates académicos y espacios de interlocución. Igualmente, permite que la comunidad educativa conozca los temas de investigación y las discusiones que se están dando entre los semilleros y grupos de investigación, para así buscar puntos de encuentro y sinergias entre los investigadores. Adicionalmente, el texto se convierte en una invitación para que se vinculen otros investigadores, docentes, estudiantes e incluso otras instituciones a los procesos investigativos coordinados desde el CIDUB

Spread of a SARS-CoV-2 variant through Europe in the summer of 2020

[EN] Following its emergence in late 2019, the spread of SARS-CoV-21,2 has been tracked by phylogenetic analysis of viral genome sequences in unprecedented detail3,4,5. Although the virus spread globally in early 2020 before borders closed, intercontinental travel has since been greatly reduced. However, travel within Europe resumed in the summer of 2020. Here we report on a SARS-CoV-2 variant, 20E (EU1), that was identified in Spain in early summer 2020 and subsequently spread across Europe. We find no evidence that this variant has increased transmissibility, but instead demonstrate how rising incidence in Spain, resumption of travel, and lack of effective screening and containment may explain the variant’s success. Despite travel restrictions, we estimate that 20E (EU1) was introduced hundreds of times to European countries by summertime travellers, which is likely to have undermined local efforts to minimize infection with SARS-CoV-2. Our results illustrate how a variant can rapidly become dominant even in the absence of a substantial transmission advantage in favourable epidemiological settings. Genomic surveillance is critical for understanding how travel can affect transmission of SARS-CoV-2, and thus for informing future containment strategies as travel resumes.S

Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial

Background: Glucagon-like peptide 1 receptor agonists differ in chemical structure, duration of action, and in their effects on clinical outcomes. The cardiovascular effects of once-weekly albiglutide in type 2 diabetes are unknown. We aimed to determine the safety and efficacy of albiglutide in preventing cardiovascular death, myocardial infarction, or stroke. Methods: We did a double-blind, randomised, placebo-controlled trial in 610 sites across 28 countries. We randomly assigned patients aged 40 years and older with type 2 diabetes and cardiovascular disease (at a 1:1 ratio) to groups that either received a subcutaneous injection of albiglutide (30–50 mg, based on glycaemic response and tolerability) or of a matched volume of placebo once a week, in addition to their standard care. Investigators used an interactive voice or web response system to obtain treatment assignment, and patients and all study investigators were masked to their treatment allocation. We hypothesised that albiglutide would be non-inferior to placebo for the primary outcome of the first occurrence of cardiovascular death, myocardial infarction, or stroke, which was assessed in the intention-to-treat population. If non-inferiority was confirmed by an upper limit of the 95% CI for a hazard ratio of less than 1·30, closed testing for superiority was prespecified. This study is registered with ClinicalTrials.gov, number NCT02465515. Findings: Patients were screened between July 1, 2015, and Nov 24, 2016. 10 793 patients were screened and 9463 participants were enrolled and randomly assigned to groups: 4731 patients were assigned to receive albiglutide and 4732 patients to receive placebo. On Nov 8, 2017, it was determined that 611 primary endpoints and a median follow-up of at least 1·5 years had accrued, and participants returned for a final visit and discontinuation from study treatment; the last patient visit was on March 12, 2018. These 9463 patients, the intention-to-treat population, were evaluated for a median duration of 1·6 years and were assessed for the primary outcome. The primary composite outcome occurred in 338 (7%) of 4731 patients at an incidence rate of 4·6 events per 100 person-years in the albiglutide group and in 428 (9%) of 4732 patients at an incidence rate of 5·9 events per 100 person-years in the placebo group (hazard ratio 0·78, 95% CI 0·68–0·90), which indicated that albiglutide was superior to placebo (p<0·0001 for non-inferiority; p=0·0006 for superiority). The incidence of acute pancreatitis (ten patients in the albiglutide group and seven patients in the placebo group), pancreatic cancer (six patients in the albiglutide group and five patients in the placebo group), medullary thyroid carcinoma (zero patients in both groups), and other serious adverse events did not differ between the two groups. There were three (<1%) deaths in the placebo group that were assessed by investigators, who were masked to study drug assignment, to be treatment-related and two (<1%) deaths in the albiglutide group. Interpretation: In patients with type 2 diabetes and cardiovascular disease, albiglutide was superior to placebo with respect to major adverse cardiovascular events. Evidence-based glucagon-like peptide 1 receptor agonists should therefore be considered as part of a comprehensive strategy to reduce the risk of cardiovascular events in patients with type 2 diabetes. Funding: GlaxoSmithKline